Insights from 2023 ASCO® Annual Meeting

 

Insights from 2023 ASCO® Annual Meeting
I

ASCO® 2023 Insights: "A Phase 1 Study of Fianlimab (anti-LAG-3) + Cemiplimab (anti-PD-1) in Patients With Advanced Melanoma - Poor-Prognosis Subgroup Analysis"

By Insights from 2023 ASCO® Annual Meeting FEATURING Inderjit Mehmi
By Insights from 2023 ASCO® Annual Meeting FEATURING Inderjit Mehmi
97 views
July 20, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

19:38
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

Featured Video

17:48
Exelixis

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma With Mul…

Feat. R. Alter, A. Rezazadeh
Skin
24:20

ASCO® 2023 Insights: "To Treat or Not to Treat - Challenging Scenari…

Insights from 2023 ASCO® Annual Meeting

K. Margolin

186 views
07:35

ASCO® 2023 Insights: "A Phase 1 Study of Fianlimab (anti-LAG-3) + Ce…

Insights from 2023 ASCO® Annual Meeting

I. Mehmi

97 views
10:21

ASCO® 2023 Insights: "Three-Year Data of PRADO and OpACIN-Neo Trials…

Insights from 2023 ASCO® Annual Meeting

I. Reijers

130 views
03:30

ASCO® 2023 Insights: "Final Clinical Results & First Translational C…

Insights from 2023 ASCO® Annual Meeting

J. Smithy

53 views
08:27

ASCO® 2023 Insights: "Significant Durable Response With Fianlimab & …

Insights from 2023 ASCO® Annual Meeting

O. Hamid

435 views
08:38

ASCO® 2023 Insights: "A Phase 3 Trial Comparing Fianlimab + Cemiplim…

Insights from 2023 ASCO® Annual Meeting

T. Panella

739 views
06:39

ASCO® 2023 Insights: "Final Analysis of Distant Metastasis-Free Surv…

Insights from 2023 ASCO® Annual Meeting

J. Luke

966 views
05:20

ASCO® 2023 Insights: "Impact of Immune Checkpoint Inhibition on Ovar…

Insights from 2023 ASCO® Annual Meeting

E. Buchbinder

730 views